PARTICIPANT INFORMATION SHEET

Study Title: FiRst in human safEty and Ease of use assessment of 400mg progesterone CallaviD® in wOMen with luteal phase insufficiency (FREEDOM)

Lead Investigator: Professor Siobhan Quenby

Local Research team: Biomedical Research Unit (BRU) Research team

Summary Page

Trial purpose: To see if 400mg progesterone Callavid® can safely deliver vaginal progesterone into the bloodstream and how well it works compared to one of the current prescribed pessaries (Cyclogest® 400mg).

Prescribed for:
luteal phase insufficiency

Products used in this trial:
These are both 400mg progesterone products used vaginally



Cyclogest® 400mg

400mg progesterone

You will be randomly assigned one product to start, then cross over to the other

Trial team: This trial is being sponsored by a women's health company called Calla Lily Clinical Care and has been reviewed and supported by the Research & Development Trial Management Unit at University Hospitals Coventry and Warwickshire (UHCW). The trial will be run at UHCW and hospital visits will take place at their Clinical Research Facility (CRF).

KEY INFORMATION:

duration	up to 4 months
number of hospital visits	up to 6 visits
blood samples	3 per hospital visit: one at the start of the visit, one after 3 hours and one after 6 hours
reimbursement	£100 per visit + £25 for interview

TO TAKE PART, YOU MUST:

- be diagnosed with luteal phase insufficiency
- have experienced one or more miscarriages
- be between 18-45 years of age
- not be pregnant or breastfeeding
- have a clear understanding of written and spoken English

Contents

Invitation to participate **4**

1. What is the purpose of this trial? **4**

a. Why have I been invited to take part? 6

2. What does taking part in this trial involve? **6**

a. Trial components 6

b. Known Side Effects of Vaginal Progesterone 7

3. Trial Process **9**

a. Participant flow chart 10

b. Round 1 11

c. Round 2 13

d. Round 3 17

e. Schedule of Events 19

4. Details of the trial **20**

a. Where is this trial taking place? 20

b. Do I have to take part? 21

c. What are the benefits? 21

d. What are the risks? 21

e. Will I receive reimbursement for taking part? 22

f. What if something goes wrong? 22

5. How will we use information about you? **23**

a. Will my taking part in this study be kept confidential? 24

b. How will we use your information after the trial ends? 24

c. What are your choices about how your information is used? 25

d. Where can you find out more about how your information is used? 25

e. What will happen to the results of this trial? 25

f. What will happen to the samples I give? 26

6. Who is involved in this trial? **26**

a. Who is organising and funding this trial? 26

b. Who has reviewed this trial? 26

c. Contact for further information 26

Invitation to participate

You are invited to take part in a research trial as you have had one or more miscarriages and have been diagnosed with luteal phase insufficiency. Before you decide to take part, it is important for you to understand why the trial is being done and what it will involve for you. This information sheet has been given to you to keep – please take time to read it carefully. Discuss it with friends, relatives or your general practitioner (GP) if you wish. It is up to you to decide whether or not to take part in this trial.

Whatever you decide, the standard of care you receive will not be affected. If there is anything that is unclear, or you would like more information, please do not hesitate to ask a member of the team.

1. What is the purpose of this trial?

Women who have been diagnosed with luteal phase insufficiency may report reduced fertility and difficulty in maintaining a pregnancy. One potential treatment for this is a progesterone pessary – a small, pellet-shaped waxy medication containing a prescribed amount of progesterone (400mg) that is inserted into the vagina and left to be absorbed. Other common uses of progesterone pessaries are in *in vitro* fertilisation (IVF) treatment and miscarriage prevention in women with a history of miscarriage (this is separate from luteal phase insufficiency).

University Hospitals of Coventry and Warwickshire (UHCW) are working with a company called Calla Lily Clinical Care (CLCC). CLCC are the trial Sponsor, meaning they have legal responsibility and oversight of the conduct of the trial. UHCW are the research team, consisting of consultant gynaecologists, research nurses and midwives. CLCC have developed a new device called Callavid® with the aim of improving women's quality of life while taking their prescriptions of vaginal progesterone. This is currently not approved for use in the UK, so we are testing it as part of this trial.

There are different makers of vaginal progesterone pessary. In this trial we will be comparing the current standard prescription, called Cyclogest® 400mg, to the CLCC product 400mg progesterone Callavid, which contains the same type

and amount of progesterone. Callavid is a tampon-shaped device that will hold the pessary in place inside the vagina. Please see images of both products below.



Figure 1. The **Cyclogest®** 400mg pessary and the usual mode of insertion.



Figure 2. The 400mg progesterone **Callavid®** product and the usual mode of insertion.

Callavid is made up of the pessary containing progesterone, which sits on top of a modified tampon, with a transparent sleeve joined to an external liner to stop any leakage.



Figure 3. Detailed diagram showing 400mg progesterone Callavid's components

The aim of this trial is to see if Callavid® can safely deliver vaginal progesterone into the bloodstream and how well it works compared to one of the current prescribed pessaries (Cyclogest® 400mg). We will also ask you how easy and comfortable you find using each option. The results will help us to design a follow-up trial that will give us more information about how well the product works in women.

a. Why have I been invited to take part?

You have been invited to take part in the FREEDOM trial as you have attended the miscarriage clinic at UHCW under the care of Professor Siobhan Quenby and have been identified as eligible. We are inviting women who are not currently pregnant, who have had one or more miscarriages, and have been diagnosed by a doctor as having luteal phase insufficiency.

2. What does taking part in this trial involve?

In this trial, we will compare the 400mg progesterone Callavid product with the Cyclogest 400mg product. The trial is split into three rounds, each lasting 7 days.

a. Trial components

- **Phone call:** A member of the research team will call you to explain the trial and answer any questions you may have. During this call, they will ask for your verbal consent to participate. The research team member will record this on a consent form, which you will then be asked to sign in person on your first visit.

- **Randomisation:** If you decide to participate, you will be randomly assigned to use either the Cyclogest® pessary or the Callavid product in the first round. You will be informed of your assigned treatment on the day of your first visit. Afterward, you will switch to the other product in the second round, which will be during your next menstrual cycle. For example, if you use Callavid® in the first round, you will use Cyclogest® in the second round.
- **Duration:** Each round lasts for 7 days.
    - **First and Second Rounds:**
        - Callavid: You will be asked to use the Callavid product twice per day (morning and evening), and to keep it inserted for 2 hours each time before removing it.
        - Cyclogest: You will use the Cyclogest pessary as prescribed in standard care, twice per day (morning and evening).
    - **Third Round:** In the third round, you will use Callavid twice daily for 3 hours each time (an additional hour compared to the first or second round). This is to help us assess the safety and usability of using Callavid for a different duration.
- **Safety reporting:** We will ask if you experience any side effects - these are called adverse events, and it is part of the trial aims that we collect this data to ensure the product is safe. If you experience any side effects during the trial, whether or not listed in **Section 2b** below, we ask you to tell us this so we can record the information.
- **Information Collection:** The research team will collect some basic information from you, including:
    - Your health details (e.g. confirmation of your luteal phase insufficiency)
    - Your previous pregnancy history
    - The date of your last period

b. Known Side Effects of Vaginal Progesterone

One of the trial's objectives is to assess the nature and occurrence of any adverse events associated with the use of Callavid compared to Cyclogest. The

progesterone used in Cyclogest and Callavid is a well-known drug that is commonly used in people who have a history of miscarriages and for IVF cycles in the UK. There are known common and uncommon side effects of using vaginal progesterone.

Common side effects from vaginal progesterone include:

- Sleepiness, fatigue (tiredness)
- Abdominal discomfort or pain, constipation
- Hot flush
- Breast pain or tenderness

Uncommon side effects include:

- Headache, dizziness, mood changes
- Change in taste, vomiting, flatulence (wind), diarrhoea, bloat (gastric dilatation)
- Night sweats, skin rash or itching
- Joint pain
- Pelvic pain, ovarian enlargement, vaginal bleeding
- Frequent urination, involuntary excretion of urine
- Weight increase
- Bleeding
- Itching at the application site, feeling cold or body temperature change or general discomfort

Taking progesterone can alter the length of your menstrual cycle (your period may start earlier than usual or it may be delayed), though the frequency of this happening is not known from the available data.

Toxic Shock Syndrome (TSS) is a rare but serious, and sometimes fatal, condition. There is a very low risk of developing TSS from regular tampon use. As Callavid® incorporates a modified tampon as one of its components, there is also a very low risk of TSS associated with its use. This risk is further minimised due to Callavid's design, which uses a less absorbent material and has a shorter wear time. TSS symptoms can develop rapidly and may initially resemble flu-like symptoms. Watch for signs like:

- Sudden high fever (over 39°C/102°F)
- Vomiting

- Diarrhoea
- Fainting or near fainting when standing up, and dizziness
- Sunburn-like rash
- Muscle aches

If you experience any of these or other side effects not on this list during the visit or the trial, we ask you to tell us this so we can record the information. This will need to be reviewed by the research team to allow recruitment to the trial to continue, as one of these could potentially be a serious adverse event (SAE), which could impact your health outcomes.

3. Trial Process

The first day of each round will start approximately 7 days before your expected period. For people with a 28-day cycle, this would be around day 21 of your cycle.

Please see the flow chart **below** that shows the process of taking part in this trial.

a. Participant flow chart



b. Round 1

i. Hospital visit (Day 1)

During this visit, you will go to the UHCW Clinical Research Facility (CRF) to receive your first dose of progesterone and complete some trial assessments. The visit will last about 6 hours. The CRF has two beds which you can use, and during your stay, lunch, refreshments, and Wi-Fi will be provided. You will be asked to:

- Re-confirm your consent by initialling and signing the consent form.
- Do a urine pregnancy test. If the test is positive, your participation in the trial will end, and you will return to usual care.
- Have blood samples taken at 0 hours, 3 hours and 6 hours.
- Be given the product you have been assigned to, and a sanitary pad if you are given Cyclogest®.
- Insert the medication vaginally in a private space such as a bathroom.
- Measure your vital signs (Callavid® only), this is a safety measure and will not be repeated at other visits.

During the waiting time, we will ask you to complete questionnaires regarding your experience with the product and your initial thoughts on it. We will also ask you if you have experienced any side effects. For a list of known side effects from the use of progesterone, please refer to the information in **Section 2b** of this document.

If you are assigned to Cyclogest, we will ask you to wear a sanitary pad provided by the hospital. After 2 hours, the used sanitary pad or used Callavid will be collected from you and stored for analysis. We want to find out how much leakage you experience with Cyclogest compared to Callavid. This is the end of the first visit.

Before you leave the CRF, you will be given the remaining doses of your assigned product. You will be reminded to take Dose 2 of the prescribed product that evening at home.

ii. At home use of products (Days 2-6)

You will have used the first dose during Visit 1. The second dose will need to be used that same evening at home. The next 10 doses will be used at home, morning

and evening (i.e. for 5 days). The pharmacy team will provide you with enough products to use twice a day. You will also be given some spare products in case you need them.

Instructions for Use

- Before using each product, read the Instructions for Use provided with the product.
- Use the product twice a day for 7 days:
  - 2 days at the hospital (Days 1 and 7)
  - 5 days at home (Days 2 - 6)
- If you forget to use the product at the scheduled time, insert it as soon as you remember, unless it is nearly time for your next dose. Do not use two doses together and aim to use the remaining doses at the correct time.
- Whilst wearing Callavid®, you will be asked not to lie down.
- When using **Callavid** in the evening, ensure you have enough time to remove it before going to sleep.

Callavid Diary

While using the Callavid product, you will be asked to complete a diary at home. In the diary, you should record:

- The time of insertion for Callavid
- The removal time for Callavid
- Your thoughts and feelings about the product

Safety Reporting

We will also give you a phone call each day to ask you if you have experienced any side effects (adverse events), which we will record as part of the study data. If you encounter any side effects that are not mentioned in **Section 2b**, please contact the research team using the following details:

- Research Team Contact:
  - Phone: 02476 964983
  - Email: BRU@uhcw.nhs.uk
- Out-of-Hours Contact: If you experience an event outside of working hours (08:00-18:00), call:
  - UHCW Switchboard: 02476 964000 and ask to be put through to the

on-call registrar for Obstetrics and Gynaecology

You will be given a card with these contact details so you can have it with you at all times.

iii. Hospital visit (Day 7)

Six days after your first visit, you will be asked to return to the CRF. Please bring any remaining unused products with you, as these will need to be returned to the pharmacy team. The visit will last about 6 hours. You will be asked to:

- Do a urine pregnancy test. If the test is positive, your participation in the trial will end, and you will return to usual care.
- Have blood samples taken at 0 hours, 3 hours and 6 hours
- Be given Dose 13 of the assigned product, and a sanitary pad if you are using Cyclogest®
- Insert the medication vaginally in a private space such as a bathroom

During the waiting time, we will ask you to complete questionnaires regarding your experience with the product and your initial thoughts on it. We will also ask you if you have experienced any side effects. For a list of known side effects from the use of progesterone, please refer to **Section 2b** of this document.

If you are assigned to Cyclogest, we will ask you to wear a sanitary pad provided by the hospital. After 2 hours, the used sanitary pad or used Callavid® will be collected from you and stored for analysis. We want to find out how much leakage you experience with Cyclogest compared to Callavid.

You will take Dose 14 of the product at home that same evening, and complete your Callavid diary.

This is the end of the first-round procedures. Round 2 will begin approximately 7 days before your next expected period, and we will contact you to arrange this.

c. Round 2

On Day 1 of Round 2, you will be asked to do a urine pregnancy test again. If the test is negative, you will switch to using the other product for Round 2. For example, if you used Cyclogest in the first round, you will switch to Callavid in the second round, and vice versa.

If the test is positive, your participation in the trial will end, and you will return to usual care.

i. Hospital visit (Day 1)

During this visit, you will go to the UHCW Clinical Research Facility (CRF) to receive the first dose of the product assigned and complete some trial assessments. The visit will last about 6 hours. You will be asked to:

- Do a urine pregnancy test. If the test is positive, your participation in the trial will end, and you will return to usual care.
- Have blood samples taken at 0 hour, 3 hours and 6 hours
- Be given the product you have been assigned to, and a sanitary pad if you are given Cyclogest
- Insert the medication vaginally in a private space such as a bathroom

During the waiting time, we will ask you to complete questionnaires regarding your experience with the product and your initial thoughts on it. We will also ask you if you have experienced any side effects. For a list of known side effects from the use of progesterone, please refer to **Section 2b** of this document.

If you are assigned to Cyclogest®, we will ask you to wear a sanitary pad provided by the hospital. After 2 hours, the used sanitary pad or used Callavid® will be collected from you and stored for analysis. We want to find out how much leakage you experience with Cyclogest compared to Callavid.

Before you leave the CRF, you will be given the remaining doses of your assigned product. You will be reminded to take Dose 2 of the prescribed product that evening at home.

ii. At home use of products (Days 2-6)

You will have used the first dose during Visit 1. The second dose will need to be used that same evening at home. The next 10 doses will be used at home, morning and evening (i.e. for 5 days). The pharmacy team will provide you with enough products to use twice a day. You will also be given some spare products in case you need them.

Instructions for Use

- Before using each product, read the Instructions for Use provided with the product.
- Use the product twice a day for 7 days:
    - 2 days at the hospital (days 1 and 7)
    - 5 days at home (days 2 - 6)
- If you forget to use the product at the scheduled time, insert it as soon as you remember, unless it is nearly time for your next dose. Do not use two doses together and aim to use the remaining doses at the correct time.
- Whilst wearing Callavid, you will be asked not to lie down.
- When using **Callavid** in the evening, ensure you have enough time to remove it before going to sleep.

Callavid Diary

While using the Callavid product, you will be asked to complete a diary at home. In the diary, you should record:

- The time of insertion for Callavid®
- The removal time for Callavid
- Your thoughts and feelings about the product

Safety Reporting

We will also give you a phone call each day to ask you if you have experienced any side effects (adverse events), which we will record as part of the study data. If you encounter any side effects that are not mentioned in **Section 2b**, please contact the research team using the following details:

- Research Team Contact:
    - Phone: 02476 964983
    - Email: BRU@uhcw.nhs.uk
- Out-of-Hours Contact: If you experience an event outside of working hours (08:00-18:00), call:
    - UHCW Switchboard: 02476 964000 and ask to be put through to the on-call registrar for Obstetrics and Gynaecology

You will be given a card with these contact details so you can have it with you at all times.

iii. Hospital visit (Day 7)

Six days after your first visit, you will be asked to return to the CRF. Please bring any remaining unused products with you, as these will need to be returned to the pharmacy team. The visit will last about 6 hours. You will be asked to:

- Do a urine pregnancy test. If the test is positive, your participation in the trial will end, and you will return to usual care.
- Have blood samples taken at 0 hour, 3 hours and 6 hours
- Be given Dose 13 of the assigned product, and a sanitary pad if you are given Cyclogest®
- Insert the medication vaginally in a private space such as a bathroom

During the waiting time, we will ask you to complete questionnaires regarding your experience with the product and your initial thoughts on it. We will also ask you if you have experienced any side effects.

For a list of known side effects from the use of progesterone, please refer to **Section 2b** of this document.

If you are assigned to Cyclogest, we will ask you to wear a sanitary pad provided by the hospital. After 2 hours, the used sanitary pad or used Callavid will be collected from you and stored for analysis. We want to find out how much leakage you experience with Cyclogest® compared to Callavid®.

This is the end of round two procedures. Before you leave, you will be given Dose 14 of the product to use at home that same evening and reminded to complete your Callavid diary.

Post-Trial Interview

After completing Rounds 1 and 2 of the trial, you will be invited to take part in an interview with one of our researchers. The interview will focus on your experiences with using Callavid compared to Cyclogest. If convenient for you and the research team, this will be undertaken at your Day 7 visit to the CRF. However, if this is not possible, we will arrange for the interview to happen at a time convenient to you within two weeks of your appointment.

- Interview Details:
    - Will last no longer than 1 hour.
    - Will be conducted on Day 7 of Round 2 at the CRF OR online / via

telephone.
- Will be audio recorded.

d. Round 3

At Day 1 of Round 3, you will be asked to do a urine pregnancy test again. If the test is positive, your participation in the trial will end, and you will return to usual care.

If the test is negative, you will continue to Round 3 of the trial. In this round, you will use Callavid again, but the duration of use will increase from 2 hours to 3 hours. The aim is to collect safety data on a longer wear time. The structure of the visit and usage will in all other respects be the same as when you used Callavid during the Round 1 or 2.

i. Hospital visit (Day 1)

During this visit, you will go to the UHCW Clinical Research Facility (CRF) to receive your first dose of 400mg progesterone Callavid and complete some trial assessments. The visit will last about 6 hours. The CRF has two beds where you can sit or lie down, and during your stay, lunch, refreshments, and Wi-Fi will be provided. You will be asked to:

- Do a urine pregnancy test. If the test is positive, your participation in the trial will end, and you will return to usual care.
- Have blood samples taken at 0 hour, 3 hours and 6 hours
- Be given Callavid
- Insert the medication vaginally in a private space such as a bathroom

During the waiting time, we will ask you to complete questionnaires regarding your experience with the product and your initial thoughts on it. We will also ask you if you have experienced any side effects. For a list of known side effects from the use of progesterone, please refer to the Safety reporting information on **Section 2b** of this document.

After 3 hours, the used Callavid® will be collected from you and stored for analysis. We want to find out how much leakage you experience with Callavid. This is the end of the first visit.

Before you leave the CRF, you will be given the remaining Callavid doses. You

will be reminded to take Dose 2 that evening at home.

ii. At home use of products (Days 2-6)

You will have used the first dose during Visit 1. The second dose will need to be used that same evening at home. The next 10 doses will be used at home, morning and evening (i.e. for 5 days). The pharmacy team will provide you with enough products to use twice a day. You will also be given some spare products in case you need them.

Instructions for Use

- Before using each product, read the Instructions for Use provided with the product.
- Use the product twice a day for 7 days:
  - 2 days at the hospital (Days 1 and 7)
  - 5 days at home (Days 2 - 6)
- If you forget to use the product at the scheduled time, insert it as soon as you remember, unless it is nearly time for your next dose. Do not use two doses together and aim to use the remaining doses at the correct time.
- Whilst wearing Callavid, you will be asked not to lie down.
- When using **Callavid** in the evening, ensure you have enough time to remove it before going to sleep.

Callavid Diary

While using the Callavid product, you will be asked to complete a diary at home. In the diary, you should record:

- The time of insertion for Callavid
- The removal time for Callavid®
- Your thoughts and feelings about the product

Safety Reporting

We will also give you a phone call each day to ask you if you have experienced any side effects (adverse events), which we will record as part of the study data. If you encounter any side effects that are not mentioned in **Section 2b**, please contact the research team using the following details:

- Research Team Contact:

- Phone: 02476 964983
- Email: BRU@uhcw.nhs.uk

- Out-of-Hours Contact: If you experience an event outside of working hours (08:00-18:00), call:
  - UHCW Switchboard: 02476 964000 and ask to be put through to the on-call registrar for Obstetrics and Gynaecology

You will be given a card with these contact details so you can have it with you at all times.

iii. Hospital visit (Day 7)

Six days after your first visit, you will be asked to return to the CRF. Please bring any remaining unused products with you, as these will need to be returned to the pharmacy team. The visit will last about 6 hours. You will be asked to:

- Do a urine pregnancy test. If the test is positive, your participation in the trial will end, and you will return to usual care.
- Have blood samples taken at 0 hour, 3 hours and 6 hours
- Be given Dose 13 of Callavid
- Insert the medication vaginally in a private space such as a bathroom

During the waiting time, we will ask you to complete questionnaires regarding your experience with the product and your initial thoughts on it. We will also ask you if you have experienced any side effects. For a list of known side effects from the use of progesterone, please refer to **Section 2b** of this document.

After 3 hours, the used Callavid will be collected from you and stored for analysis. We want to find out how much leakage you experience with Callavid.

You will take Dose 14 of the product at home that same evening and complete the last entry into the Callavid diary.

This is the end of the third-round procedures and end of your involvement in the trial.

e. Schedule of Events

Please see a simple schedule of events below showing what will happen at each visit.

Trial activity	Rounds 1, 2 and 3		
	Visit 1 (Day 1) At UHCW	Day 2-6 At Home	Visit 2 (Day 7) At UHCW
Urine pregnancy test - once per visit	✓		✓
Use of product - morning and evening	✓	✓	✓
Blood samples - 3 per visit	✓		✓
Callavid® diary - twice per day (Callavid rounds only)	✓	✓	✓
Trial questionnaires	✓		✓
Sanitary pad/Callavid collection	✓		✓
Adverse event monitoring	✓	✓	✓
Vital signs monitoring (Round 1 only)	✓		
Semi-structured interviews (Round 2 only)			✓*

*This will be conducted online/via phone if not done at visit 2

4. Details of the trial

a. Where is this trial taking place?

The trial will take place at University Hospitals Coventry and Warwickshire, in the clinical research facility (CRF). This is a specific room that has hospital beds and some machines we need to perform observations (e.g. blood pressure) and is a quiet area where you can sit whilst you are taking part in the trial. This website will show you what the unit is like: https://research.mededcoventry.org/Research-Facilities/Coventry-and-Warwickshire-Clinical-Research-Facility

Getting to UHCW - there are several buses that can get you to the hospital, please see this website for more information about public transport and other ways of getting here: https://www.uhcw.nhs.uk/contact-us/university-hospital/.

Parking can be challenging so please ensure you have enough time before your appointment to find a space.

b. Do I have to take part?

No, you do not have to take part. We will go through this information sheet with you and answer any questions you may have. If you do agree to take part, you will be asked to sign a consent form - this might be over the phone or in person. You are free to withdraw at any time without giving a reason. You can withdraw by letting the research team know – their details are at the end of this information sheet. If you decide not to take part, or to withdraw at any time, the standard of care you receive at this hospital will not be affected in any way. If you become pregnant whilst on the trial, you will be withdrawn. If you experience any side effects that are classed as 'serious' (serious adverse events, or SAEs), you may be withdrawn, depending on the expectedness of the event. We will also keep any information or samples we have collected about you up to the point you withdraw, as agreed on the consent form.

c. What are the benefits?

We cannot guarantee any specific benefits to taking part in this research, however, you can request to have the results of the blood tests shared with you, for example the blood levels of progesterone.

Although we cannot guarantee the outcome of this study, part of the reason for conducting the research is to find a more convenient and acceptable way to deliver progesterone treatment to women undergoing IVF or who are at risk of threatened miscarriage. The most likely benefits from this research will be people undergoing treatment for these in the future.

400mg progesterone Callavid® is an investigational medicinal product being used as part of this trial, and will not be available for trial participants to use once the trial has ended.

d. What are the risks?

The progesterone used in Cyclogest® and Callavid is a well-known drug that is commonly used in people who have a history of miscarriages and for IVF cycles in the UK. There are known common and uncommon side effects of using vaginal

progesterone (please see **Section 2b** for list of side effects).

If anyone experiences a side effect (adverse event) at any point in the trial we may alter the dose of the treatment, or we will ask you to stop taking it altogether depending on the seriousness of the side effect and the drug you are taking.

You will be asked to record if any of these effects occur during your participation in this trial. If you experience any unusual effects like those mentioned on **Section 2b**, or any that are not listed there, you will need to contact the research team as this may be called a serious adverse event (SAE), and it may affect the recruitment of new patients to the trial. If you experience any effects, whether serious or not, we will make sure we monitor your progress throughout the trial and until the side effect has recovered.

As the drug used in this trial (progesterone) is used to support pregnancy and improve pregnancy outcomes we do not anticipate any negative impacts on pregnancy.

e. Will I receive reimbursement for taking part?

Yes, you will be reimbursed a daily rate of £100 for each visit you attend. For the days you are at the CRF we will provide tea, coffee, snacks and lunch. We will also cover reasonable childcare costs for the day and reasonable travel and parking reimbursement. We will also reimburse your time if you agree to take part in an interview after Round 2 at a rate of £25 per hour, with an additional £5 to cover home working costs if this is conducted online.

These research payments may have implications for you, and it is your responsibility to declare any relevant payments received (NOT including travel or childcare reimbursements) to HM Revenue & Customs for income tax purposes.

This is especially important if you are in receipt of any welfare benefits, as receiving more than the weekly/monthly or annual permitted allowance may prevent you receiving certain benefits. Please speak to the research team if you have concerns about this.

f. What if something goes wrong?

Whilst we do not anticipate problems arising during this trial, if you have any

concerns about any aspect of this trial during your involvement, you should ask to speak with the researchers who will do their best to answer your questions.

If you remain unhappy and wish to complain you can do this through the National Health Service complaints mechanisms, you can find a guide here:

https://www.nhs.uk/contact-us/how-to-complain-to-the-nhs/

To speak to someone at the Sponsor organisation about the clinical trial or the product, please contact:

Trial Support at Calla Lily Clinical Care:
Email address: clinicaltrials@callali.ly
Telephone no: 020 7754 5400

As the sponsor, Calla Lily Clinical Care (CLCC) provides insurance for the management and conduct of this trial. When you are in the hospital for trial visits, UHCW NHS Trust provides indemnity (a type of insurance). In the unlikely event that you are harmed by taking part in this trial, you would be compensated without having to prove the sponsor was at fault. . If you suspect that the harm is the result of someone's negligence then you may have grounds for legal action. You may have to bear the costs of any such legal action and you should seek legal advice about this.

For independent advice on research, you can contact PALS (Patient Advice and Liaison Service) on freephone: 0800 028 4203, email: feedback@uhcw.nhs.uk

In the unlikely event of you losing your capacity to consent during the course of the trial, you would be discontinued from taking part in the trial.

5. How will we use information about you?

We will need to use information from you and from your medical records for this research trial.

This information will include your:

- hospital number
- age

- previous medical history.

People will use this information to do the research, or to check your records to make sure that the research is being done properly. People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead.

Calla Lily Clinical Care (CLCC) is the Sponsor of this research. CLCC is responsible for looking after your information. We will share your information related to this research project with the following types of organisations:

- Universities
- Hospitals

We will keep all information about you safe and secure by:

- Storing the trial records in locked cabinets in secure locations
- Using secure, encrypted data transfer methods
- Storing electronic data on password protected computer drives

Your data will not be shared outside of the UK.

a. Will my taking part in this study be kept confidential?

If you consent to take part in the trial, all information which is collected about you during the course of the research will be kept strictly confidential. Your GP will not be directly involved in the trial but will be informed that you are taking part, as this trial involves your safety. You have the right to decline for us to contact your GP, however this may affect your medical care if there were any safety concerns whilst taking part in the trial.

b. How will we use your information after the trial ends?

Once we have finished the trial, we (The Sponsor) will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that you took part in the trial.

Your identifiable trial data will be kept for a maximum of 12 months. The trial data will then be fully anonymised, which means no one will be able to identify you from the data, securely archived for 25 years and then destroyed.

c. What are your choices about how your information is used?

- You can stop being part of the trial at any time, without giving a reason, but we will keep information about you that we already have.
- You have the right to ask us to access, remove, change or delete data we hold about you for the purposes of the trial. You can also object to our processing of your data. We might not always be able to do this if it means we cannot use your data to do the research. If so, we will tell you why we cannot do this.
- If you agree to take part in this trial, you will have the option to take part in future research using your data saved from this trial. We will ask you if we can keep your email address in a separate secure document, in order to contact you about the results of this trial. You do not have to agree to this.

d. Where can you find out more about how your information is used?

You can find out more about how we use your information:

- the Health Research Authority's leaflet available from https://www.hra.nhs.uk/patientdataandresearch
- by asking one of the research team
- by sending an email to the Sponsor's Data Protection Officer at clinicaltrials@callali.ly
- by ringing us on 020 7754 5400

e. What will happen to the results of this trial?

We will publish our results in research journals and through conferences. No information on the research data that we present will be able to identify you. We will work with our Patient and Public Involvement (PPI) contributors to find out the best way of sharing the trial results, as we want the information to be as accessible as possible to the public. If you agree to it, we will email you the results of the trial, though this may not be for a while after your participation has ended. You can also find out more information and the results of the trial once it has been published at this website: https://freedom.callali.ly/

You are also welcome at any time to contact the research team for trial updates

or more information about the findings of this trial, their details are at the end of this information sheet.

f. What will happen to the samples I give?

The blood samples you give as part of this trial will be sent to a laboratory at UHCW NHS Trust and will be analysed for your progesterone levels. Once this analysis has happened, the blood samples will be destroyed as per the hospital standard operating procedures. The sanitary pads and used Callavid® products that we collect will be stored in the Arden Tissue bank at UHCW, before being sent to a contracted lab for analysis. They will be destroyed once analysed as per laboratory standard operating procedures. All samples (blood, Callavid, and sanitary pads) will be pseudonymised, which means that they can't be identified without a 'key' that links them to your details. This key will be held by the research team at the hospital and no one will be given access to it without approval from the Chief Investigator.

6. Who is involved in this trial?

a. Who is organising and funding this trial?

This trial is being sponsored by CLCC and has been reviewed and supported by the Research & Development team at UHCW. The trial has been funded by the National Institute for Health and Social Care Research (NIHR), reference NIHR206502.

b. Who has reviewed this trial?

This trial has been independently reviewed by Health and Social Care Research Ethics Committee B, reference: 25/NI/0165.
Health Research Authority (HRA) Approval was granted on 17th Feb 2026.

c. Contact for further information

If you require further information or have any questions, please contact:

BRU Research team
Address: 2nd Floor, Opposite Ward 24, Clifford Bridge Road, Coventry, CV2 2DX
Telephone: 02476 964983
Email: BRU@uhcw.nhs.uk

Thank you for reading this information and for considering taking part in this research.